Stocklytics Platform
Asset logo for symbol FATE
Fate Therapeutics
FATE51
$2.68arrow_drop_down2.89%-$0.07
Penny Stock
Asset logo for symbol FATE
FATE51

$2.68

arrow_drop_down2.89%

Income Statement (FATE)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$45.08M-$51.06M-$48.07M-$56.01M-$62.56M
EBITDA-$40.36M-$46.24M-$43.19M-$51.27M-$58.09M
gross Profit$2.05M-$2.89M-$3.20M-$2.79M-$3.53M
NET Income-$38.42M-$48.00M-$44.12M-$45.17M-$52.75M
total Revenue$6.77M$1.92M$1.67M$1.94M$933.00K

Balance Sheet (FATE)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt$63.64M-$19.25M$61.66M$71.62M$59.54M
stockholders Equity$396.98M$426.11M$368.41M$402.77M$437.75M
total Assets$528.81M$569.89M$506.21M$543.78M$584.75M
total Debt$100.56M$102.07M$103.53M$104.95M$106.34M
total Liabilities$131.83M$143.77M$137.80M$141.01M$147.00M

Cash Flow (FATE)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$1.27M$95.48M-$180.00K$0.00$58.00K
free Cash Flow-$32.35M-$33.43M-$36.81M-$38.83M-$30.69M
investing Cash Flow----$33.16M
operating Cash Flow-$32.30M-$33.35M-$36.63M-$38.27M-$28.49M

Fate Therapeutics (FATE) Financials

Fate Therapeutics Inc (FATE) is a biopharmaceutical company focused on the development of innovative cellular immunotherapies for the treatment of cancer and other diseases. The company's financials show a strong performance in recent years. The income statement for FATE reveals consistent growth in total revenue, gross profit, and net income from stockholders. The company has been able to generate substantial revenue through its successful research and development efforts. The balance sheet of FATE reflects a healthy financial position, with significant cash equivalents, stockholders' equity, and total assets.
FATE's financials also indicate a prudent approach to managing debt. The company has a relatively low level of net debt and total liabilities, mitigating potential financial risks. The cash flow statement of FATE provides insights into the company's cash management strategies. The operating cash flow has been positive, demonstrating the company's ability to generate cash from its core operations. Additionally, FATE has maintained a positive free cash flow, indicating a strong financial position to pursue future growth opportunities.
The financing cash flow for FATE reflects the company's use of external funding sources to support its operations and investments. This includes activities such as issuing stock, repurchasing shares, and obtaining funds through debt financing. The investing cash flow represents FATE's investment in property, plant, and equipment, as well as acquisitions or divestitures of other businesses. These investments are crucial for the company's long-term growth and expansion.
In summary, Fate Therapeutics Inc (FATE) has demonstrated a strong financial performance, with consistent growth in revenue and profitability. The company's financial position is robust, with healthy cash reserves, low debt levels, and a strong balance sheet. FATE's cash flow statement reflects prudent cash management strategies, positive operating cash flow, and a healthy free cash flow. Overall, FATE's financials indicate a solid foundation for future growth and success.
add Fate Therapeutics  to watchlist

Keep an eye on Fate Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level